YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 91 Publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M{njUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\lXWxGPzJiaB?= NGXE[2FFVVOR MmPTTWM2OD1yLkCwPUDDuSByLkCwNFkh|ryP NF3Ob3ozPTZ3OUezNS=>
M-07e MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uzfFczKGh? NFLufVFFVVOR M{jETGlEPTB;MD6wOFAhyrFiMD6wNVMh|ryP MXKyOVY2QTd|MR?=
THP-1 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYi3NkBp NGPneYtFVVOR MoDiTWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? MVeyOVY2QTd|MR?=
CMK M4LOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDSeWw4OiCq M{DPW2ROW09? M4fwbmlEPTB;MD6wOVMhyrFiMD6wNFkh|ryP MlX0NlU3PTl5M{G=
MV4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3NkBp M3rPZ2ROW09? NULa[JI2UUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= NG\PSYczPTZ3OUezNS=>
AML-193 M1\ZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrRO|IhcA>? NGrhV3pFVVOR MXXJR|UxRTBwNE[yJOKyKDBwME[wJO69VQ>? MYGyOVY2QTd|MR?=
HL-60 NV\HeVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXeyW4VsPzJiaB?= MoPkSG1UVw>? M4nSTmlEPTB;MD6wNFEhyrFiMD6wNFAzKM7:TR?= Mlf5NlU3PTl5M{G=
ML-2 NHfyZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\2O|IhcA>? NG\ZUmlFVVOR NILJd5lKSzVyPUCuNFA6KMLzIECuNFAzKM7:TR?= NUXrRZJmOjV4NUm3N|E>
OCI/AML3 MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLxO|IhcA>? MkPzSG1UVw>? MlnmTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? MkDINlU3PTl5M{G=
HEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv3fXE4OiCq MmPvSG1UVw>? MXjJR|UxRTBwNUW5JOKyKDBwMEO4JO69VQ>? M2PpT|I2PjV7N{Ox
ME-1 NFfMOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvIO|IhcA>? NHz6XZVFVVOR NYrHSGc2UUN3ME2wMlY5PCEEsTCwMlE4QSEQvF2= NWrURlRtOjV4NUm3N|E>
THP-1 M1ThXWFxd3C2b4Ppd{BCe3OjeR?= NHvjVWIyyqEQvF2= MXe3NkBp MoDrSG1UVw>? MkPTbY5lfWOnczDhdI9xfG:|aYO= MVmyOVY2QTd|MR?=
M-07e Mmj5SpVv[3Srb36gRZN{[Xl? NFXzb2kx6oDVMdMg{txO MWC3NkBp MYjEUXNQ M1;UVIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NXnVfII4OjV4NUm3N|E>
THP-1 NXS2bm9bTnWwY4Tpc44hSXO|YYm= NYDIN5UxOOLCk{JCpO69VQ>? MV23NkBp MojJSG1UVw>? Mn3obY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MkDSNlU3PTl5M{G=
CMK MlzSSpVv[3Srb36gRZN{[Xl? NIXjcJQx6oDVMdMg{txO MoXEO|IhcA>? NVTBUoJWTE2VTx?= Mnr1bY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NHOxWYIzPTZ3OUezNS=>
AML-193 NHu1SVNHfW6ldHnvckBCe3OjeR?= M3jPSlDjiJNzwrFOwG0> NXLadIs{PzJiaB?= MV7EUXNQ MWPpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw NILIcm4zPTZ3OUezNS=>
Kasumi-1 MYHGeY5kfGmxbjDBd5NigQ>? MVmw5qCUOcLizszN M37PblczKGh? M4HOfmROW09? NVHJcoh5cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NEfTWGozPTZ3OUezNS=>
MV4-11 NFfFd4VHfW6ldHnvckBCe3OjeR?= M1m1WFDjiJNzwrFOwG0> NE\zPG84OiCq NHK4[opFVVOR MlvwbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= MkLMNlU3PTl5M{G=
MUG-Chor  NEjOSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMVUh|ryP M2fqfVI1NzR6IHi= MlnrTWM2OD15LkC15qCKdk1iZn;yJFQ5cA>? NHjtXGQzPTZ2MEG4OS=>
U-CH1  MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnJZpJ[OC13IN88US=> MX2yOE81QCCq M{TBcGlEPTB;OT6wN-KBkW6PIH\vdkA1QGh? NXW5T2RHOjV4NECxPFU>
KATOIII NHLSU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPrXmZDOTBxMkCgcm0> NVvsZ2c3PDhiaB?= M3TaWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWXQWWExOjV4M{WwOVU>
AGS  NYHNfoc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPiNVAwOjBibl2= MljjOFghcA>? NHr4T3dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVGyOVY{PTB3NR?=
SACC-83 NYrmN|lLTnWwY4Tpc44hSXO|YYm= MlvHOUBvVQ>? NYq5N4JuPDhiaB?= NGHrdoVl\WO{ZXHz[ZMhdnWlbHXhdkBmgHC{ZYPzbY9vKG:oIFjJSk0y|rF? MYqyOVQ5PTZ|NR?=
INA-6 NInT[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxbpMxNTVyMDDuUS=> MXe0PEBp MX;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoTqNlUzQTZ7N{i=
U-266 M2XD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMVUxOCCwTR?= MUK0PEBp NHHxOHJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXiyOVI6Pjl5OB?=
MOLP-8 M37vfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOwMVUxOCCwTR?= M{fLRVQ5KGh? M3\mWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIizdHEzPTJ7Nkm3PC=>
HG-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMVUxOCCwTR?= NFz6UnA1QCCq M3SxfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWCyOVI6Pjl5OB?=
NCI-H929 NWmzTVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH1WGwxNTVyMDDuUS=> MmTTOFghcA>? NFT6TlBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYmyOVI6Pjl5OB?=
OPM-2 M4XQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjiNXd1OC13MECgcm0> NGT1N2o1QCCq NES2VmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1e2UFI2Ojl4OUe4
L-363 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nUdVAuPTByIH7N M4ewblQ5KGh? MnnhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M33Fd|I2Ojl4OUe4
MOLP-2 NWPXPXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXMNE02ODBibl2= MWG0PEBp M4CxXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGDhcHMzPTJ7Nkm3PC=>
KMS-12-BM Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu0VHIzOC13MECgcm0> NEK2S241QCCq NHnE[ItqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2rSSlI2Ojl4OUe4
SK-MM-2 NWjrUoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITPU5MxNTVyMDDuUS=> NYL1cIVqPDhiaB?= NF7iWnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHqNlUzQTZ7N{i=
U-266 MYLBdI9xfG:|aYOgRZN{[Xl? MV[wMVUxKG6P MYKyOEBp MYfpcoR2[2W|IHHwc5B1d3Orcx?= M3v2TFI2Ojl4OUe4
INA-6  M4LXbWFxd3C2b4Ppd{BCe3OjeR?= MlywNE02OCCwTR?= NVLjd|lVOjRiaB?= NXrsdlh2cW6mdXPld{BieG:ydH;zbZM> MWiyOVI6Pjl5OB?=
MCF7 NFrlVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi3NkBp NFfkdYNKSzVyPUGzJOKyKDZibl2= NXTpO5pEOjV{MkCyNlU>
MCF7-TamR6 NYnkdHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknNO|IhcA>? NH\nVIFKSzVyPUigxtEhPiCwTR?= NUO5PYZjOjV{MkCyNlU>
MCF7-TamR7 M2HtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLIO4M4OiCq MkDUTWM2OD16INMxJFMhdk1? NWDveHk3OjV{MkCyNlU>
MCF7-TamR8 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qV4lUPzJiaB?= NEfrSZRKSzVyPUG1JOKyKDZibl2= NWP2T|ZnOjV{MkCyNlU>
MCF7-TamC3 M2PUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j3Z|czKGh? MX\JR|UxRTZiwsGgN{BvVQ>? Mmi1NlUzOjB{MkW=
MCF7-TamC6 M2Pjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\PZ404OiCq MoDBTWM2OD14INMxJFAvOSCwTR?= NEDU[YMzPTJ{MEKyOS=>
MDA-MB-231 M3\iZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[1b2w6PzJiaB?= M2DE[GlEPTB;NTFCtUAyKG6P NIXSTJMzPTJ{MEKyOS=>
SK-BR-3 NVH2eHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofrO|IhcA>? NXraZZNEUUN3ME23JOKyKDBwMzDuUS=> MVeyOVIzODJ{NR?=
Eca109 NUTJcGI3TnWwY4Tpc44hSXO|YYm= MV6xMVUxKG6P MWm0PEBp NUnVdZk4TE2VTx?= M3KyUJN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NH:3XGIzPTF|OUO5OS=>
TE13 NVqzNIwxTnWwY4Tpc44hSXO|YYm= NIrOWGQyNTVyIH7N NIHhVIo1QCCq M3G1UGROW09? MY\zeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M4\LUlI2OTN7M{m1
Eca109 M1HUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;XVVAuOTByIH7N NV;OdWt6OjRxNEigbC=> MkfPSG1UVw>? NI[2dJll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVvoPYc{OjVzM{mzPVU>
TE13 NGHK[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H3PFAuOTByIH7N M4DlW|I1NzR6IHi= NF\idJdFVVOR NF:5dZNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWCyOVE{QTN7NR?=
MT-3 M{foVmtqdmG|ZTDBd5NigQ>? MonTO|IhcA>? NXfQUJFXTE2VTx?= NULHTo9YUUN3ME2yMlg3KMLzIECuOVQhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NIDORXMzPDh4NkW4OS=>
MDA-MB-468 MYPLbY5ie2ViQYPzZZk> MkSzO|IhcA>? M4fEUWROW09? NEfUUXRKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? Mm\kNlQ5PjZ3OEW=
SUM-159 NV;ldpJWU2mwYYPlJGF{e2G7 NFH4N2Q4OiCq M4jR[2ROW09? NVrNe|lTUUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w NEDadWwzPDh4NkW4OS=>
MT-3 NULtNWI{U2mwYYPlJGF{e2G7 NYXWdoJUPzJiaB?= NGDlOXdFVVOR M3;rU2lEPTB;NUSuNVEhyrFiND6zNkBvVSCob4KgSHI2KGW6cILld5Nqd25? M{XabFI1QDZ4NUi1
MDA-MB-468 M4rIdWtqdmG|ZTDBd5NigQ>? NELkRZI4OiCq MWXEUXNQ NVfXfllrUUN3ME2wMlA4KMLzIECuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M{nwZlI1QDZ4NUi1
SUM-159 NFPNTnpMcW6jc3WgRZN{[Xl? M3HpPFczKGh? NInzbpdFVVOR NUDKbYFlUUN3ME22PU41KMLzIESuNlMhdk1iZn;yJGRTPSCneIDy[ZN{cW:w NFrmWHkzPDh4NkW4OS=>
MT-3 + NAC MV7LbY5ie2ViQYPzZZk> Mki1O|IhcA>? NEntc3hFVVOR NXvVNJFNUUN3ME21Ok4zKMLzIEKuNFchdk1iZn;yJGRTPSCneIDy[ZN{cW:w MVGyOFg3PjV6NR?=
MT-3 + SB203580 NIDhVYdMcW6jc3WgRZN{[Xl? MWe3NkBp MVnEUXNQ NILqPZFKSzVyPUO4MlQyKMLzIEWuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w M2j1blI1QDZ4NUi1
DB NF21fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;RNVAhdk1? MUSyOEBp NVXRSoJlTE2VTx?= MlzWbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u MXWyOFQ5PjV7NR?=
SU-DHL-8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYixNEBvVQ>? MWWyOEBp M3fRWmROW09? MVPpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36= MofMNlQ1QDZ3OUW=
WSU-DLCL2 NXe1OZRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrZNVAhdk1? NU\UTFV2OjRiaB?= NWmyV|RNTE2VTx?= MnHKbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M4[0b|I1PDh4NUm1
ACC-2 M3TQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfiSlExNTFyMDDuUS=> M4X5dFI1KGh? NHfieXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlXpNlQ{PzB7OUW=
ACC-2 NFLoSIJCeG:ydH;zbZMhSXO|YYm= M4TMT|AuOjBibl2= M4\LbFI1KGh? MoWybY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MVuyOFM4ODl7NR?=
ACC-2 MkW1SpVv[3Srb36gRZN{[Xl? MXmwMVIxKG6P MkXNNlQhcA>? MWnpcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? MlzNNlQ{PzB7OUW=
BFTC905 NIDNWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvpc3AxNTFyMECgcm0> NHvaOJc1QCCqwrC= NVjLUoVsTE2VTx?= NUX4T5Q6UUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHSyTXQzPDJ7N{[0OC=>
T24 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5fHYxNTFyMECgcm0> MXe0PEBpyqB? MoDaSG1UVw>? M4jYd2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlTFNlQzQTd4NES=
TSGH8301  NGf6Z3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PKSFAuOTByMDDuUS=> MlHUOFghcMLi MV3EUXNQ M1LkV2lEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGnnSHEzPDJ7N{[0OC=>
BFTC909 M2K3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[wMVExODBibl2= NIXTfJU1QCCqwrC= MX\EUXNQ NULLWWM4UUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWS3ZY51OjR{OUe2OFQ>
BFTC905 M1\WU2Fxd3C2b4Ppd{BCe3OjeR?= M3;G[|IxKG6P M4SxblQ5KGh? MUjEUXNQ M{Hieolv\HWlZYOgZZBweHSxc3nz NWrDeGdROjR{OUe2OFQ>
BFTC905 NETWdVNHfW6ldHnvckBCe3OjeR?= MmH2NlAhdk1? Mm\zOFghcA>? MmKySG1UVw>? M3O0cIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ NV;SPXNSOjR{OUe2OFQ>
A2780p MlvISpVv[3Srb36gRZN{[Xl? MnqyNE0yODBibl2= NYPaNGx2OjRiaB?= NGToTlJFVVOR NYi2WoVGcW6mdXPld{BUfXK4aY\pckBld3ewcnXneYxifGmxbtMg NUDhbplJOjR{NkK4O|U>
A2780cis M2XqeGZ2dmO2aX;uJGF{e2G7 MonxNE0yODBibl2= NH61SFIzPCCq NXHmepo3TE2VTx?= M2rETYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= NYe5XpkxOjR{NkK4O|U>
A2780p MUjBdI9xfG:|aYOgRZN{[Xl? M4rybVUuOTByIH7N NXTk[lZvOjRxNEigbC=> M{P2NWROW09? NWTkXXB5cW6lcnXhd4V{KGGyb4D0c5NqeyCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFS5ZlczPDJ4Mki3OS=>
A2780cis M{nlWGFxd3C2b4Ppd{BCe3OjeR?= NIrBR2g2NTFyMDDuUS=> NWK3SFJIOjRxNEigbC=> MUjEUXNQ M3rWNIlv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NUTZZXB1OjR{NkK4O|U>
SH-SY5Y NYfSSVR{SXCxcITvd4l{KEG|c3H5 NV3vcIJsOS9zMD:xNFAhyrWP M3TxUVczKGh? MULEUXNQ NUCzS3BKcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUHQdWlWOjR{NUS1OlA>
HL-60 NUDTe2p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDhNGc4OsLiaB?= M3nISGROW09? MYHJR|UxRTBwMzDuUS=> MmHhNlM3OTh6NkK=
U937  MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rv[lczyqCq NYLte4VmTE2VTx?= M3m4[mlEPTB;MD64JI5O MlXNNlM3OTh6NkK=
HL-60  M4DBbmZ2dmO2aX;uJGF{e2G7 MnTUNeKh|ryP MlmyOk8yOi9{NDDo M3fzcWROW09? NF3PS4lqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> M1vxVVI{PjF6OE[y
U937  MUXGeY5kfGmxbjDBd5NigQ>? NYnlNpBCOcLizszN MkTuOk8yOi9{NDDo MU\EUXNQ NVnCcFkzcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MmPWNlM3OTh6NkK=
HL-60 M{H4e2Fxd3C2b4Ppd{BCe3OjeR?= M37rVlAvOS9zIN88US=> NVTBNlF1QCCq M1riS2ROW09? NUfhepdLcW6mdXPld{BieG:ydH;zbZM> MXiyN|YyQDh4Mh?=
Sk-NEP-1  MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxMVExODByIH7N MXSyOEBp NUm5TJRETE2VTx?= NIjIdYpKSzVyPUGwNEBvVQ>? MkPONlMzPjd4OUm=
SK-NEP-1  NV7WcnBxSXCxcITvd4l{KEG|c3H5 NXruRpdpPTBxMUCwJI5O NWK5Xpg{OTJxMkSgbC=> NIK5U5RFVVOR NX;TTGZTcW6mdXPld{BieG:ydH;zbZM> MWeyN|I3PzZ7OR?=
TC-32 NX\5TXRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjpNE4yNTFyMECgcm0> MUHFR|UxRTNwMDDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnTBNlI6PjF5NkO=
TC-71 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMlEuOTByMDDuUS=> NHy0Nm1GSzVyPUWuO{BvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFjzNG4zOjl4MUe2Ny=>
SK-ES-1 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfOOZgxNjFvMUCwNEBvVQ>? MmPSSWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHziSHkzOjl4MUe2Ny=>
RD-ES MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nTclAvOS1zMECwJI5O NVXWSG1OTUN3ME22MlIhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH23OFkzOjl4MUe2Ny=>
HEK293 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\IZ41pOC5zLUGwNFAhdk1? M1u3c2VEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml;rNlI6PjF5NkO=
M059J NVyw[IZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqzSpIxNTVyIH7N M1nHbFQ5KGh? MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NG\6XVUzOjd5MEGxNC=>
M059K MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMVUxKG6P MlHKOFghcA>? NWfnfHRtcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoL1NlI4PzBzMUC=
M059J NF;j[ZFCeG:ydH;zbZMhSXO|YYm= MUWzNEBvVQ>? MW[yOEBp M1XSW4lv\HWlZYOgZZBweHSxc3nz NGj4V3IzOjd5MEGxNC=>
M059K MW\BdI9xfG:|aYOgRZN{[Xl? NY\PdGFwOzBibl2= MViyOEBp NVLuTWkzcW6mdXPld{BieG:ydH;zbZM> M1PJelIzPzdyMUGw
PANC-1 NGD1UmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3GwS|AvODFvMUCwNEBvVQ>? NEL3[oI1QCCq NVHo[3Q4UUN3ME2zMlY6KG6P MWmyNlczOzh5MR?=
MIAPaCa-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLO[W0xNjBzLUGwNFAhdk1? MkfNOFghcA>? NU[zUZk1UUN3ME2yPU4{PiCwTR?= MYOyNlczOzh5MR?=
BxPC-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLoNE4xOS1zMECwJI5O Mon2OFghcA>? NH3BW5ZKSzVyPUOwMlI3KG6P NEHwXpMzOjd{M{i3NS=>
PANC-1 NEXNU3hHfW6ldHnvckBCe3OjeR?= NYPYU|VtOC1zMECwJI5O NWXHTXhUOjRiaB?= Ml3ObY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u MlThNlI4OjN6N{G=
MIAPaCa-2 M3TZW2Z2dmO2aX;uJGF{e2G7 NWLGWIY{OC1zMECwJI5O MoO1NlQhcA>? NVP3R4N{cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBZUUGSIHHu[EB{fXK4aY\pckBmgHC{ZYPzbY9v MWSyNlczOzh5MR?=
BxPC-3 MmC5SpVv[3Srb36gRZN{[Xl? MUiwMVExODBibl2= MVyyOEBp MknxbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u NY\QNW1QOjJ5MkO4O|E>
RPMI-7951 NXjVfo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu0e2pZT0l3ME2zMlIhdk1? NIO3NWYzOTd|N{WwNi=>
SK-MEL-5 NF35bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf6S|ZIUTVyPUSuNkBvVQ>? NH3jbnEzOTd|N{WwNi=>
A375 Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rLPWdKPTB;Nj6zJI5O MkDsNlE4Ozd3MEK=
SK-MEL-28 M3;od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXCUXB7T0l3ME23MlYhdk1? M3LZWVIyPzN5NUCy
SK-MEL-2 NXPVXG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7HTVUxRTFzIH7N NXLDV406OjF5M{e1NFI>
DB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTyRZY1QMLiaB?= MlLhS2k2OD1|LkWgcm0> NV\LSoNHOjF{M{e1NFg>
Pfeiffer MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHGUG04PDkEoHi= MUDHTVUxRTNwOTDuUS=> NIO2WZUzOTJ|N{WwPC=>
SU-DHL-5 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLwfWY1QMLiaB?= MXLHTVUxRTBwMkOgcm0> NYjyOXFWOjF{M{e1NFg>
SU-DHL-8 M1zrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvROFjDqGh? NXXYTmZLT0l3ME2xMlQhdk1? NITVRWIzOTJ|N{WwPC=>
WSU-DLCL-2 NHLsclRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTnfGFvPDkEoHi= NIHnU|hIUTVyPUGuOEBvVQ>? NXPveoxKOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID